Date | Open(₹) | High(₹) | Low(₹) | Close(₹) | No. Of Trades(₹) | Total Turnover(₹) | Deliverable Quantity(₹) |
|---|---|---|---|---|---|---|---|
13-May-2026 | 439 | 452.5 | 435.05 | 438.85 | 21,927 | 22,42,11,853.3 | 2,17,950 |
14-May-2026 | 438.35 | 453.8 | 432.5 | 450.5 | 16,328 | 20,97,17,285.1 | 1,98,860 |
15-May-2026 | 452.3 | 491.95 | 450 | 478.4 | 64,323 | 1,16,77,80,672.75 | 9,27,776 |
18-May-2026 | 479 | 493.2 | 473.05 | 476.2 | 34,135 | 48,32,17,200.4 | 4,25,592 |
19-May-2026 | 476.95 | 490.75 | 464.15 | 472.45 | 26,165 | 26,35,07,912.25 | 1,69,934 |
20-May-2026 | 471.15 | 483.8 | 466.85 | 476.3 | 19,749 | 18,14,25,252.85 | 1,79,409 |
21-May-2026 | 479.9 | 486.85 | 468.05 | 474.65 | 18,008 | 30,32,09,196.4 | 3,14,291 |
22-May-2026 | 479.8 | 518.55 | 475.1 | 490.25 | 1,17,121 | 2,60,98,13,875.3 | 12,70,437 |
25-May-2026 | 500 | 529.8 | 495.9 | 512.15 | 1,05,855 | 2,28,93,08,470.3 | 12,76,402 |
26-May-2026 | 515 | 519 | 492.15 | 504.85 | 35,563 | 81,32,27,222.4 | 5,68,768 |
27-May-2026 | 505 | 506.9 | 483.35 | 491.8 | 25,450 | 51,97,05,593.25 | 4,83,017 |
29-May-2026 | 494 | 509.8 | 491 | 498.95 | 23,939 | 53,15,62,992.2 | 4,87,157 |
01-Jun-2026 | 504.5 | 509.8 | 493.4 | 499.25 | 22,370 | 38,95,30,072.55 | 3,49,102 |
02-Jun-2026 | 499.6 | 526.55 | 494.05 | 517.35 | 59,721 | 1,47,76,53,739.9 | 13,61,111 |
03-Jun-2026 | 521 | 525 | 502.4 | 515.4 | 39,575 | 91,65,10,590.5 | 6,31,985 |
04-Jun-2026 | 517.95 | 532.2 | 509.15 | 525.8 | 25,586 | 68,67,84,297.8 | 6,09,256 |
05-Jun-2026 | 530.15 | 543 | 524.4 | 538.05 | 41,524 | 95,24,23,055.9 | 6,90,715 |
08-Jun-2026 | 530 | 558.95 | 526 | 532.5 | 46,993 | 1,07,95,81,333.4 | 8,46,151 |
09-Jun-2026 | 536.9 | 578.8 | 533 | 569.15 | 30,085 | 78,57,16,255.3 | 5,97,212 |
10-Jun-2026 | 572 | 581 | 555.55 | 558.8 | 25,328 | 57,33,21,009.85 | 4,05,804 |
11-Jun-2026 | 553 | 568.8 | 535.95 | 538.85 | 24,329 | 38,29,01,398.6 | 2,88,124 |
12-Jun-2026 | 549.9 | 556.75 | 538.2 | 546.75 | 19,226 | 35,73,03,245.75 | 3,02,125 |
It targets to initiate first-in-human clinical trials in patients with Essential Thrombocythemia and Polycythemia Vera.
Here are some of the stocks that may see significant price movement today: Larsen & Toubro, Lodha Developers, Shilpa Medicare, etc.
USFDA conducted the Good Manufacturing Practices (GMP) inspection from October 24 to October 30 in 2024.
The certification came after a successful inspection by the Finnish Medicines Agency on behalf of EMA from March 10 to March 14, 2025
The partnership will work on a new biological entity (NBE) in the immuno-oncology field to better treat cancer.
Here are some of the stocks that may see significant price movement today: Aditya Birla Real Estate, Shilpa Medicare, Swiggy, etc.
No regulatory issues were raised by the USFDA at Unit-2 during the inspection, the company said in a regulatory filing.
Shilpa Medicare said it has completed Phase 3 trials for SMLNUD07 – Nor Ursodeoxycholic Acid (Nor UDCA) tablets in 165 NAFLD patients in India.
The certification followed a successful inspection by the European Medicines Agency, Austria, held from September 24 to September 26 at the Nacharam, Hyderabad facility.
This FDA approval is a milestone in cancer therapy as it presents a more convenient and precise alternative to the traditional tablet forms.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, PMS SEBI Regn. No: INP000002213, IA SEBI Regn. No: INA000000623, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
